Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telatinib in Advanced Solid Tumors
NCT03175497Phase 1Completed
- Sponsor
- EOC Pharma
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telatinib in solid tumor and gastric cancer (GC), sponsored by EOC Pharma. Primary endpoints: Dose-limiting toxicity at 23 days and Treatment-emergent adverse events at 23 days. Started Jul 2017; status: completed.
02
Drugs
telatinib
03
Conditions
solid tumorgastric cancer (GC)
Beyond the preview
Go deeper on NCT03175497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175497.